Abstract
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.
MeSH terms
-
Clinical Trials, Phase III as Topic
-
Double-Blind Method
-
Humans
-
Randomized Controlled Trials as Topic
-
Receptors, Vascular Endothelial Growth Factor
-
Recombinant Fusion Proteins / adverse effects
-
Recombinant Fusion Proteins / therapeutic use*
-
United States
-
United States Food and Drug Administration
-
Wet Macular Degeneration / drug therapy*
Substances
-
Recombinant Fusion Proteins
-
aflibercept
-
Receptors, Vascular Endothelial Growth Factor